Ignite Creation Date:
2024-05-06 @ 10:37 AM
Last Modification Date:
2024-10-26 @ 12:32 PM
Study NCT ID:
NCT03304548
Status:
COMPLETED
Last Update Posted:
2019-04-02
First Post:
2017-10-02
Brief Title:
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension PAH Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Qualitative Research to Explore Patient Preference for Modes of Administration in Pulmonary Arterial Hypertension Treatments
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GlaxoSmithKline GSK is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 ACE2 This new treatment may require subcutaneous administration in comparison to current treatments which are taken orally Hence GSK would like to conduct this qualitative interview study with PAH subjects to explore subjects perspective and preferences for various modes of treatment administration daily or weekly subcutaneous injection versus current treatment options This will be a qualitative study comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to 10 PAH subjects each approximately 30 minutes in duration in the United States US
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None